GSK: The Worst Is Finally Over (Rating Upgrade) - Seeking Alpha

Oct 10, 2024 · GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable at 12.4x. Explore more details here.

CouponFollow Extension

6%
OFF

GSK: The Worst Is Finally Over (Rating Upgrade) - Seeking Alpha

2 weeks from now

Oct 10, 2024 · GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable at 12.4x. Explore more details here.

seekingalpha.com

4%
OFF

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After …

2 weeks from now

3 days ago · In the fourth quarter of 2024, sales rose 4% at constant currencies to 8.12 billion pounds, above the 7.83 billion pounds that analysts had expected, according to a consensus …

morningstar.com

6%
OFF

ViiV Reports Positive Real-world Data For HIV Prevention Drug - MSN

2 weeks from now

GSK: The Worst Is Finally Over (Rating Upgrade) Pfizer: Investor Activism Is Not The Solution; Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential

msn.com

20%
OFF

Anyone Using Alpha Picks From Seeking Alpha? : R/stocks - Reddit

2 weeks from now

I have used Alpha Picks since Sept. 2023 and am up 20%. But if you annualize my gains over the 131 days, you get an annual rate of gain of 55.01%. And if you go further and calculate the …

reddit.com

2%
OFF

GSK Dips As Lower Vaccine Sales Weigh On Q3 2024 Results - MSN

2 weeks from now

Seeking Alpha. GSK dips as lower vaccine sales weigh on Q3 2024 results ... GSK’s overall revenue grew ~2% on the same basis to £8.0B as the company’s General and Specialty …

msn.com

FAQs about GSK: The Worst Is Finally Over (Rating Upgrade) - Seeking Alpha Coupon?

Is the worst now behind GSK?

Seeking Alpha analyst and Investing Group leader, Manika Premsingh believes the worst is now behind GSK, adding that even though there is risk to core EPS growth of forecasts 10-12% for the full year 2024 if they reflect the Zantac charge, it's still not enough to impact the stock's attractiveness. ...

Why is GSK stock downgraded to a hold?

GSK's strong H1 24 earnings report indicates risks for investors, due to a weaker outlook and the Zantac trial. See why GSK stock is downgraded to a hold. ...

What happened to GSK (GSK)?

GSK (NYSE: GSK) continued losses for a seventh straight session as the stock closed 0.61% lower, at $37.51 on Friday. The British pharmaceutical company lost 3.13% in the last six trading sessions. The stock has gained 1.46% so far this year, compared to an over 21% rise in the broader S&P 500 Index. GSK is down 8% over the past one month. ...

Should you buy GSK (GSK) stock?

Seeking Alpha’s Quant rating has rated GSK stock as a HOLD with a score of 3.37 out of 5, with an A+ on profitability, and an F on the prospect of growth. Among Wall Street analysts, 4 out of 7 analysts recommend BUY and above, 2 recommend HOLD, while only one recommends SELL. ...

Why did GSK's share price surge 6% Yesterday?

GSK's share price surged 6% yesterday in the biggest rise seen since December 2022, after the company settled 93% of cases related to the Zantac litigation. The settlement will be reflected in Q3 2024 results, with a GBP 1.8 billion charge expected to impact the earnings per share by GBP 0.44. ...

Why did GSK stock close 0.63% lower on Thursday?

The stock closed 0.63% lower, at $37.74 on Thursday. GSK (GSK) on Thursday said that its RSV vaccine elicited a robust immune response in recipients aged 18 to 49 years who were at increased risk of developing lower respiratory tract disease as a result of the virus due to an underlying medical condition or being immunocompromised. ...